{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:46:25Z","timestamp":1756460785520},"reference-count":52,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2003,12,19]],"date-time":"2003-12-19T00:00:00Z","timestamp":1071792000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bipolar Disorders"],"published-print":{"date-parts":[[2003,12]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Bipolar disorder is a complex condition including depression, mania, and in many cases associated with comorbid anxiety symptoms and substance abuse. Mood stabilizers including lithium and divalproex have been considered standard therapy for the treatment of patients with bipolar disorder, but remission rates remain inadequate. Conventional antipsychotics have demonstrated efficacy for acute mania, but they appear to have little role in the maintenance treatment of bipolar disorder. Despite substantial evidence of efficacy and recent guideline recommendations, atypical antipsychotics remain underused for the treatment of bipolar disorder. Data from double\u2010blind, controlled trials are available for a number of clinically meaningful efficacy measures, including improvement in manic symptoms, onset of action, response rates, remission rates, improvement in comorbid depressive symptoms, and induction\/worsening of mania or depression. Atypical antipsychotics are effective both as alternatives to lithium or divalproex as monotherapy, or in combination with these mood stabilizers, in the acute and likely the maintenance treatment of mania. The atypical antipsychotics represent an effective and relatively safe addition to our armamentarium for the treatment of bipolar disorder.<\/jats:p>","DOI":"10.1111\/j.1399-2406.2003.00060.x","type":"journal-article","created":{"date-parts":[[2003,12,19]],"date-time":"2003-12-19T09:08:22Z","timestamp":1071824902000},"page":"7-19","source":"Crossref","is-referenced-by-count":20,"title":["Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics"],"prefix":"10.1111","volume":"5","author":[{"given":"Lakshmi N","family":"Yatham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,12,19]]},"reference":[{"key":"e_1_2_16_2_2","volume-title":"World Health Report: Mental health: New Understanding, New Hope.","author":"World Health Organization.","year":"2001"},{"key":"e_1_2_16_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.6.530"},{"key":"e_1_2_16_4_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1210"},{"key":"e_1_2_16_5_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.1.133"},{"key":"e_1_2_16_6_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0109"},{"key":"e_1_2_16_7_2","first-page":"3","article-title":"Recent advances in treatment of acute mania","volume":"11","author":"Chou J.","year":"1991","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"e_1_2_16_8_2","first-page":"38","article-title":"Antipsychotic agents and bipolar disorder","volume":"59","author":"Tohen M","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_16_9_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1019628"},{"key":"e_1_2_16_10_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.165.6.827"},{"key":"e_1_2_16_11_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.148.6.723"},{"issue":"5","key":"e_1_2_16_12_2","first-page":"43","article-title":"Tardive dyskinesia in affective disorders","volume":"60","author":"Kane J.","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_16_13_2","first-page":"1","article-title":"Practice guideline for the treatment of patients with bipolar disorder (revision)","volume":"159","author":"American Psychiatric Association.","year":"2002","journal-title":"Am J Psychiatry"},{"key":"e_1_2_16_14_2","unstructured":"HirschfeldR KeckP KarcherK KramerM GrossmanF VietaE.Rapid antimanic effect of risperidone monotherapy: A 3\u2010week multicenter double\u2010blind placebo\u2010controlled trial [Abstract NR182]. Presented at 156th APA Annual Meeting San Francisco CA May 17\u201322 2003."},{"key":"e_1_2_16_15_2","unstructured":"VietaE KhannaB GrossmanF Van KammenD KramerM.Risperidone in the treatment of manic or mixed episodes of bipolar disorder [Abstract]. Presented at ACNP Puerto Rico 2002."},{"key":"e_1_2_16_16_2","unstructured":"GopalS KramerM OlsenM SteffensD.Mania remission rates in a randomized\u2010controlled trial of risperidone [Abstract NR515]. Presented at 156th APA Annual Meeting San Francisco CA May 17\u201322 2003."},{"key":"e_1_2_16_17_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania. The Olanzapine HGEH Study Group","volume":"156","author":"Tohen M","year":"1999","journal-title":"Am J Psychiatry"},{"key":"e_1_2_16_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.9.841"},{"key":"e_1_2_16_19_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.741"},{"key":"e_1_2_16_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(02)80408-4"},{"key":"e_1_2_16_21_2","unstructured":"EerdekensM KarcherK GrossmanF KramerM.Risperidone monotherapy in acute bipolar mania. Presented at the World Psychiatric Association Meeting Vienna Austria June 18\u201321 2003."},{"key":"e_1_2_16_22_2","unstructured":"JonesM HuizarK.Quetiapine monotherapy for acute mania associated with bipolar disorder (STAMP 1 and STAMP 2) [Abstract NR432]. Presented at 156th APA Annual Meeting San Francisco CA May 17\u201322 2003."},{"key":"e_1_2_16_23_2","first-page":"176","article-title":"Risperidone compared with both lithium and haloperidol in mania: a double\u2010blind randomized controlled trial","volume":"21","author":"Segal J","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_16_24_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.6.1011"},{"key":"e_1_2_16_25_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1210"},{"key":"e_1_2_16_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199911000-00003"},{"key":"e_1_2_16_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200209000-00003"},{"key":"e_1_2_16_28_2","doi-asserted-by":"crossref","unstructured":"TohenM GoldbergJ Gonzales\u2010PintoAet al.A 12\u2010week double blind comparison of olanzapine versus haloperidol in the treatment of acute mania.Arch General Psychiatry2003(in press).","DOI":"10.1001\/archpsyc.60.12.1218"},{"key":"e_1_2_16_29_2","unstructured":"BourinM AubyP MarcusRet al.Aripiprazole versus haloperidol for maintained treatment effect in acute mania [Abstract NR467]. Presented at 156th APA Annual Meeting San Francisco CA May 17\u201322 2003."},{"key":"e_1_2_16_30_2","unstructured":"BakerR ZarateC JrBrownE SchuhL TohenM.A three\u2010week comparison of olanzapine versus risperidone in the treatment of bipolar mania: improvement in manic and depressive symptoms and treatment adherence [Abstract 15]. Presented at 156th APA Annual Meeting San Francisco CA May 17\u201322 2003."},{"key":"e_1_2_16_31_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.7.1146"},{"key":"e_1_2_16_32_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.182.2.141"},{"key":"e_1_2_16_33_2","unstructured":"MullenJ DevineN SweitzerD.Quetiapine adjunctive therapy for acute mania associated with bipolar disorder (SIAM) [Abstract NR482]. Presented at 156th APA Annual Meeting San Francisco CA May 17\u201322 2003."},{"key":"e_1_2_16_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200210000-00011"},{"key":"e_1_2_16_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.1.62"},{"key":"e_1_2_16_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(02)80202-4"},{"key":"e_1_2_16_37_2","unstructured":"CanusoC ZhuY BossieC GrossmanF.Remission with risperidone in combination With mood stabilizers in acute bipolar mania [Abstract NR503]. Presented at 156th APA Annual Meeting San Francisco CA May 17\u201322 2003."},{"key":"e_1_2_16_38_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2003.02237.x"},{"key":"e_1_2_16_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00334-8"},{"key":"e_1_2_16_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(02)00335-X"},{"key":"e_1_2_16_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(02)80451-5"},{"issue":"1","key":"e_1_2_16_42_2","article-title":"Cognitive function associated with olanzapine in the treatment of acute mania: is cognitive improvement a marker of clinical improvement in manic symptoms? [Abstract P 2 E 057]","volume":"5","author":"Shi L","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_16_43_2","first-page":"231","article-title":"Long\u2010term effects of the treatment with risperidone versus conventional neuroleptics on the neuropsychological performance of euthymic bipolar patients","volume":"28","author":"Reinares M","year":"2000","journal-title":"Actas Esp Psiquiatr"},{"key":"e_1_2_16_44_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0907"},{"key":"e_1_2_16_45_2","unstructured":"TohenM BowdeC CalabreseJet al.Olanzapine versus placebo for relapse prevention in bipolar disorder [Abstract NR197]. Presented at 156th APA Annual Meeting San Francisco CA May 17\u201322 2003."},{"key":"e_1_2_16_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(02)80334-0"},{"key":"e_1_2_16_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(02)80454-0"},{"issue":"1","key":"e_1_2_16_48_2","article-title":"Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomized double\u2010blind controlled 12\u2010month clinical trial [Abstract]","volume":"4","author":"Tohen M","year":"2002","journal-title":"Bipolar Disord"},{"key":"e_1_2_16_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(02)80450-3"},{"key":"e_1_2_16_50_2","unstructured":"TohenM KetterT CalabreseJet al.Long\u2010term use of olanzapine or olanzapine\/fluoxetine for bipolar depression [Abstract NR510]. Presented at 156th APA Annual Meeting San Francisco CA May 17\u201322 2003."},{"key":"e_1_2_16_51_2","unstructured":"YathamLN BinderC RicardelliR ConnolyM LeblaneJ KusumakarV.Risperidone in acute and continuation treatment of mania. Int Clin Psychopharmacol2003;18:237\u2013244."},{"key":"e_1_2_16_52_2","unstructured":"KhannaS HirschfeldR KarcherK GrossmanF KramerM.Risperidone monotherapy in acute bipolar mania [Abstract NR424]. Presented at 156th APA Annual Meeting San Francisco CA May 17\u201322 2003."},{"key":"e_1_2_16_53_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1011"}],"container-title":["Bipolar Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-2406.2003.00060.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-2406.2003.00060.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T09:06:44Z","timestamp":1695805604000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-2406.2003.00060.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":52,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["10.1111\/j.1399-2406.2003.00060.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-2406.2003.00060.x","archive":["Portico"],"relation":{},"ISSN":["1398-5647","1399-5618"],"issn-type":[{"value":"1398-5647","type":"print"},{"value":"1399-5618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}